The market is up 1.8% over the last week and has climbed 28% over the past year, with earnings forecast to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. We've selected three examples of penny stocks that combine balance sheet strength with potential for outsized gains, giving investors a chance to discover hidden value in quality companies.

Underneath we present a selection of stocks filtered out by our screen.

TROOPS (TROO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: TROOPS, Inc., along with its subsidiaries, offers consultancy services for insurance products across Hong Kong, Australia, and the People’s Republic of China, with a market cap of $476.42 million.

Operations: TROOPS, Inc. has not reported any specific revenue segments.

Market Cap: $476.42M

TROOPS, Inc., with a market cap of US$476.42 million, operates in the consultancy sector for insurance products across Asia-Pacific regions. Despite being unprofitable and having a negative return on equity of -56.92%, the company has shown significant sales growth from US$10.07 million to US$17.1 million over the past year while reducing its losses over five years at a rate of 41.8% annually. TROOPS is debt-free and maintains more than three years of cash runway despite shrinking free cash flow by 34% per year, indicating financial resilience amidst high share price volatility and uncovered short-term liabilities.

Anavex Life Sciences (AVXL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anavex Life Sciences Corp. is a biopharmaceutical company with a market cap of approximately $255.77 million.

Operations: Anavex Life Sciences Corp. does not currently report any revenue segments.

Market Cap: $255.77M

Anavex Life Sciences Corp., with a market cap of US$255.77 million, is currently pre-revenue and unprofitable, facing challenges such as increased losses over the past five years and a negative return on equity of -31.55%. The company recently received a Nasdaq delinquency notice for delayed SEC filings but remains listed while working to regain compliance. Despite these hurdles, Anavex has no debt and sufficient cash runway exceeding three years. Recent executive changes include appointing Dr. Terrie Kellmeyer as Interim CEO to steer its strategic initiatives in advancing clinical development programs amidst high share price volatility.

GoPro (GPRO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: GoPro, Inc. is a company that offers cameras, mountable and wearable accessories, and subscription services across various regions including the Americas, Europe, the Middle East, Africa, and the Asia Pacific with a market cap of approximately $206.13 million.

Operations: The company's revenue is primarily generated from its Photographic Equipment & Supplies segment, amounting to $651.54 million.

Market Cap: $206.13M

GoPro, Inc., with a market cap of US$206.13 million, has launched the MISSION 1 Series cameras featuring advanced technology like the GP3 processor. Despite its innovative product line, GoPro remains unprofitable with increasing losses over five years and a negative return on equity of -122.13%. The company is exploring strategic alternatives including potential sale options to unlock value. While short-term liabilities exceed assets, GoPro maintains sufficient cash runway for over a year and has reduced its debt-to-equity ratio from 101% to 83.5% in five years, though share price volatility remains high.

Taking Advantage

• Embark on your investment journey to our 331 US Penny Stocks selection here.
• Seeking Other Investments? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.